Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma

Completed

Conditions studied: Renal Cell Carcinoma

In brief

A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: * Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as second-line therapy after Sunitinib (Sutent) or Bevacizumab (Avastin) for first-line therapy (about 100 patients) * Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as first-line therapy followed by Sunitinib (Sutent) as second-line therapy (about 100 patients)

Key facts

Study ID

NCT00876382

Run by

SCRI Development Innovations, LLC

People needed

47

Starts

2009-05-01

Expected to finish

2011-08-01

Last updated by the study team

2013-11-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Eligible patient cases are those that have received Sorafenib (Nexavar) as second-line therapy after Sunitinib (Sutent) or Bevacizumab (Avastin) for first-line therapy or those patients that were treated with Sorafenib (Nexavar) as first-line therapy followed by Sunitinib (Sutent) as secondline therapy.

Where it is running

• Northeast Arkansas Clinic — Jonesboro, Arkansas, United States
• Gulfcoast Oncology Associates — St. Petersburg, Florida, United States
• Medical Oncology Associates of Augusta — Augusta, Georgia, United States
• Consultants in Blood Disorders and Cancer — Louisville, Kentucky, United States
• Jackson Oncology Associates — Jackson, Mississippi, United States
• St. Louis Cancer Care — Chesterfield, Missouri, United States
• Oncology Hematology Care — Cincinnati, Ohio, United States
• Tennessee Oncology, PLLC — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.